NCT06500026View on ClinicalTrials.gov

A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

714

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Small Cell Lung Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Topotecan

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY